Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

NCCN 2.2026ESMO Living GuidelinesLast reviewed: Apr 2026

HER2+ Breast Cancer: Treatment Guidelines

Comprehensive HER2+ management — from neoadjuvant TCHP/DB-11 to the DESTINY-Breast09 era in metastatic disease. pCR-guided adjuvant strategy, ILD management, and triple-positive sequencing.

HER2+ Treatment Algorithm at a Glance

Early Stage HER2+

T1a/T1b N0

Upfront Surgery → APT regimen (wP + Trastuzumab ×12 wks)

10-year DFS ~91.3% (APT trial)

T1c (gray zone)

Either: upfront surgery + APT OR neoadjuvant TCHP/THP

ESMO increasingly favors neoadjuvant for pCR assessment

T2+ or N+

Neoadjuvant preferred: TCHP or THP (PHERGain/TRAIN-3 approaches)

DB-11 for high-risk: pCR ~62.5–67.3%

Post-Neoadjuvant (Adjuvant)

pCR Achieved (ypT0/is ypN0)

Continue Trastuzumab ± Pertuzumab to complete 1 year total HER2 therapy

HR+ patients: add extended endocrine therapy

Residual Disease

T-DXd (DB-05, Category 1 preferred) or T-DM1 (KATHERINE) — 14 cycles

T-DXd iDFS HR 0.47; T-DM1 iDFS HR 0.50

Metastatic HER2+ (Stage IV) — DESTINY-Breast09 Era

1st Line

T-DXd + Pertuzumab (DB-09) — PFS 40.7 mo; FDA approved Dec 15, 2025

THP if high ILD risk or prior adjuvant T-DXd

2nd Line

T-DXd mono (DB-03) if not used 1L; Tucatinib triplet for CNS disease

DB-03: PFS 29.0 mo; 5-yr OS ~48%

3rd Line+

T-DM1 / Tucatinib + T-DM1 (HER2CLIMB-02) / Margetuximab / Zanidatamab

Maintain HER2 blockade throughout all lines

2025–2026 Major Practice Changes

DESTINY-Breast09 (Dec 2025)

T-DXd + Pertuzumab replaces THP as preferred 1L metastatic HER2+ — PFS 40.7 vs 26.9 months (HR 0.56); FDA approved December 15, 2025

DESTINY-Breast05 (2025/2026)

T-DXd now Category 1 preferred for residual disease, replacing T-DM1 in high-risk settings (iDFS HR 0.47 vs T-DM1)

DESTINY-Breast11 (DB-11, 2025/2026)

Neoadjuvant T-DXd + Pertuzumab achieves pCR ~62.5%; T-DXd→THP sequence pCR 67.3%; being integrated for high-risk neoadjuvant

APHINITY OS 2025

Final OS data confirms Pertuzumab benefit in N+ early HER2+ (HR 0.81, OS benefit in high-risk/N+ patients)

HER2CLIMB-05 (SABCS 2025)

Tucatinib + HP maintenance post-taxane: PFS 24.9 vs 16.3 months (HR 0.641); new intensification option

DB-03 FINAL (December 2025)

T-DXd final analysis: median OS 56.4 vs 42.7 months vs T-DM1; 5-year OS ~48%; 2L standard when not used 1L

Frequently Asked Clinical Questions

When should I use upfront surgery vs neoadjuvant therapy for HER2+ BC?
Upfront surgery is indicated for T1a/T1b N0 tumors (≤1.0 cm, node-negative). APT regimen (Paclitaxel + Trastuzumab ×12 weeks) gives 10-year DFS ~91.3%. T1a (<5mm): observation or chemo de-escalation. T1b (5-10mm): wP + Trastuzumab (APT regimen). T1c (>10mm) or N+: neoadjuvant preferred. ESMO Living Guidelines increasingly favor neoadjuvant even for T1c to assess pCR.
How has DESTINY-Breast09 changed 1L metastatic HER2+?
DESTINY-Breast09 established T-DXd + Pertuzumab as the new preferred first-line standard for metastatic HER2+ breast cancer, FDA approved December 15, 2025. Median PFS 40.7 months vs 26.9 months for THP (HR 0.56, p<0.00001). ORR 85.1% vs 78.6%; complete response 15.1% vs 8.5%. HR+ subgroup: median PFS 38.0 months. ILD incidence ~12%. THP still indicated if high ILD risk or prior adjuvant T-DXd.
When should I use T-DXd vs T-DM1 for residual disease?
DESTINY-Breast05 data (2025/2026) established T-DXd as Category 1 preferred for residual disease, superior to T-DM1. KATHERINE established T-DM1 as reducing recurrence risk 50% vs trastuzumab (iDFS HR 0.50). Integration principle: if T-DXd used neoadjuvantly (DB-11) and pCR achieved → standard trastuzumab/pertuzumab adjuvant; if residual disease → T-DXd preferred per DB-05.
How do I manage T-DXd ILD in HER2+ breast cancer?
ILD incidence ~12-15%, Grade 5 fatality ~0.5-1%. Grade 1 (asymptomatic, imaging only): HOLD + steroids 0.5 mg/kg; rechallenge if resolves <28 days (same dose), or dose reduce if >28 days (e.g., 5.4→4.4 mg/kg). Grade 2 (symptomatic, mild): PERMANENT STOP + steroids 1 mg/kg. Grade 3 (severe, O2 needed): PERMANENT STOP + methylprednisolone 1-2 mg/kg. Grade 4 (life-threatening): PERMANENT STOP + methylprednisolone 2-4 mg/kg. Steroid taper ≥6 weeks for Grade 2-4 — rapid taper = risk of fatal rebound.
How do I manage triple-positive (HR+/HER2+) metastatic breast cancer?
1L: T-DXd + Pertuzumab (DB-09); PFS 40.7 months (HR+ subgroup: 38.0 months). If using THP: consider PATINA maintenance (HP + AI + Palbociclib; PFS 44.3 vs 29.1 months) or HER2CLIMB-05 (Tucatinib + HP maintenance). 2L: T-DXd or Tucatinib triplet. 3L: MonarchHER (Abemaciclib + Trastuzumab + Fulvestrant; PFS 7.3 months, chemo-free option).
When do I prioritize Tucatinib in metastatic HER2+ breast cancer?
Tucatinib + Trastuzumab + Capecitabine (HER2CLIMB) is the preferred option for active brain metastases in 2L — significant OS benefit in CNS-active disease, CNS ORR 47%, 36% reduction in CNS progression risk. HER2CLIMB-05 maintenance (Tucatinib + HP) shows benefit across all subgroups including brain mets. TBCRC049 (2026): Tucatinib triplet for leptomeningeal mets; OS ~10 months.

Clinical Decision Support

Integrated clinical scoring tools for HER2+ breast cancer patient assessment:

ECOG Performance Status

Assess functional status before therapy selection

Charlson Comorbidity Index

Estimate comorbidity burden; inform T-DXd candidacy and ILD risk

G8 Geriatric Screening

Frailty screening for older patients with HER2+ breast cancer

CARG Chemotherapy Toxicity

Geriatric assessment for chemotherapy toxicity prediction (TCHP candidacy)

Khorana VTE Risk Score

Thromboprophylaxis risk assessment in metastatic setting

Clinical reference only. These guidelines are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines. Guideline versions: NCCN 2.2026, ESMO Living Guidelines.